PROKARIUM
29.7.2021 10:02:11 CEST | Business Wire | Press release
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Uz Stammberger, MD, as Chief Medical Officer. In the role, Dr. Stammberger will lead the advancement of Prokarium’s oncology pipeline into the clinic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005044/en/
“Uz brings extensive clinical experience to Prokarium’s team having spent more than two decades in oncology drug development and research,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “We are thrilled to welcome Uz onboard as we expand our clinical portfolio into oncology, and I look forward to working together on the development of our next generation immuno-oncology pipeline.”
“Prokarium’s unique technology based on live, attenuated bacteria is a promising and powerful strategy for reprogramming the tumor microenvironment and eliciting long-lasting anti-tumor effects,” said Dr. Stammberger. “I am excited to exploit the full therapeutic capabilities of our proprietary bacteria in both the monotherapy and combination settings, with our lead program targeting bladder cancer, an indication in which there remains a significant unmet medical need for patients.”
Dr. Stammberger joins Prokarium from the Novartis Institutes for BioMedical Research, where he oversaw the MAPK assets in Translational Clinical Oncology and generated several PoCs/PoMs in different genetically defined solid tumors. Prior to his role at Novartis, Dr. Stammberger was a Clinical Lead at Merck KGaA, responsible for Tepotinib, a small molecule inhibitor of c-Met which is approved in the US and Japan for MetEx14 skip mutant NSCLC. Earlier in his career, he held various positions at Roche and Boehringer Ingelheim. Dr. Stammberger received his Doctor of Medicine as well as the Venia docendi (Adj. Professor of General Thoracic Surgery) from the University of Bern and is a board-certified GP and surgeon.
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based London, UK. For further information, visit https://www.prokarium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TradingHub Secures Strategic Investment From Nordic Capital to Accelerate Next Phase of Growth16.3.2026 17:00:00 CET | Press release
TradingHub, a leading provider of trade surveillance technology for global financial institutions, has agreed to partner with Nordic Capital which will become the company’s majority shareholder. The investment marks a significant milestone in TradingHub’s journey and provides strong backing to support the company’s continued growth and innovation. Existing investor Summit Partners and TradingHub’s co-founder Neil Walker will continue to hold minority positions in the company following the close of the transaction. With the support of Nordic Capital, TradingHub will accelerate its expansion across global markets while continuing to invest in the development of its trade surveillance platform. The company plans to further strengthen its capabilities across asset classes, including equities, and continue its expansion into new markets and geographies. Founded in 2010 and today operating from offices in London, Toronto, Singapore and Sydney, TradingHub has built a highly differentiated tec
Madinah Hosts Third Umrah and Ziyarah Forum with Strong International Participation16.3.2026 16:10:00 CET | Press release
The third edition of the Umrah and Ziyarah Forum will commence in Madinah on Monday, March 30, 2026. The forum is organized by the Ministry of Hajj and Umrah, in partnership with the Pilgrim Experience Program, at the King Salman International Convention Center, with wide participation from business leaders, decision-makers, and specialists in the Umrah and Ziyarah services ecosystem from around the world to exchange expertise and explore ways to further enrich the experience of the Guests of Allah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316471639/en/ Madinah Hosts Third Umrah and Ziyarah Forum with Strong International Participation (Photo: AETOSWire) This year’s edition builds on the success of the forum's previous editions, reaffirming its position as a global platform for advancing the Umrah and Ziyarah services ecosystem. It focuses on enhancing services for Umrah performers and visitors, in line with the gro
Capcom’s Official Street Fighter 6 World Championship Tournaments Attract Record-high 20,000 Attendees16.3.2026 14:00:00 CET | Press release
– Capcom aims to accelerate growth of the global competitive scene with a larger total prize pool of over $2.1 million in the upcoming 2026 season – Capcom Co., Ltd. (TOKYO:9697) today announced that Capcom Cup 12 and Street Fighter League: World Championship 2025, its official world championship tournaments to determine the top Street Fighter 6 competitors, which were held at Ryogoku Kokugikan Arena from March 11-15, achieved a record-high of 20,000 attendees, concluding with great success. At Capcom Cup 12, which features matches against individual players, SAHARA (21 years old), who is a first‑year professional player, claimed the championship title in his debut appearance, while in the team-based competition Street Fighter League: World Championship 2025, Japanese representatives REJECT were the winning team. Capcom additionally announced that it will hold next season’s Capcom Cup 13 and Street Fighter League: World Championship 2026 at Ryogoku Kokugikan Arena. Furthermore, the com
Capcom’s Resident Evil Requiem Sales Exceed 6 Million Units!16.3.2026 14:00:00 CET | Press release
– Capcom also plans to release additional game content – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, now exceed 6 million units, which is the fastest that a title in the series has reached this milestone. Resident Evil Requiem is the latest installment in the Resident Evil series, which offers photorealistic visuals and a deep sense of immersion. Players can enjoy the elevated essence of the survival horror experience by the interplay between intense fear and exhilarating action, made possible by two protagonists. Going forward, Capcom plans to implement several measures, such as ongoing support and additional game content, so players can continue to enjoy the title longer. In addition, the Resident Evil series will celebrate its 30th anniversary on March 22,2026. Capcom is readying various plans for this anniversary to delight series fans, such as a collaboration between Universal Studios Japan and Residen
Helical Fusion Announces Construction Site for Phase 1 of “Helix HARUKA,” Marking Transition to Manufacturing and Assembly of Fusion Hardware16.3.2026 14:00:00 CET | Press release
Advances one of Japan’s leading public-private partnership initiatives for fusion commercialization with NIFS and industrial partners Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316066384/en/ Concept image of Helix HARUKA, Helical Fusion’s integrated demonstration device Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the National Institute for Fusion Science (NIFS), located on the NIFS campus. Helical Fusion has already begun manufacturing phase and site build-out, with the aim of conducting coil current (ene
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom